66 related articles for article (PubMed ID: 8651936)
1. Mapping of DNA topoisomerase II poisons (etoposide, clerocidin) and catalytic inhibitors (aclarubicin, ICRF-187) to four distinct steps in the topoisomerase II catalytic cycle.
Sehested M; Jensen PB
Biochem Pharmacol; 1996 Apr; 51(7):879-86. PubMed ID: 8651936
[TBL] [Abstract][Full Text] [Related]
2. The topoisomerase II poison clerocidin alkylates non-paired guanines of DNA: implications for irreversible stimulation of DNA cleavage.
Gatto B; Richter S; Moro S; Capranico G; Palumbo M
Nucleic Acids Res; 2001 Oct; 29(20):4224-30. PubMed ID: 11600711
[TBL] [Abstract][Full Text] [Related]
3. Development of water-soluble prodrugs of the bisdioxopiperazine topoisomerase IIβ inhibitor ICRF-193 as potential cardioprotective agents against anthracycline cardiotoxicity.
Bavlovič Piskáčková H; Jansová H; Kubeš J; Karabanovich G; Váňová N; Kollárová-Brázdová P; Melnikova I; Jirkovská A; Lenčová-Popelová O; Chládek J; Roh J; Šimůnek T; Štěrba M; Štěrbová-Kovaříková P
Sci Rep; 2021 Feb; 11(1):4456. PubMed ID: 33627707
[TBL] [Abstract][Full Text] [Related]
4. Chromatin damage generated by DNA intercalators leads to degradation of RNA Polymerase II.
Espinoza JA; Kanellis DC; Saproo S; Leal K; Martinez JF; Bartek J; Lindström MS
Nucleic Acids Res; 2024 May; 52(8):4151-4166. PubMed ID: 38340348
[TBL] [Abstract][Full Text] [Related]
5. ATM inhibitor KU60019 synergistically sensitizes lung cancer cells to topoisomerase II poisons by multiple mechanisms.
Shu J; Wang X; Yang X; Zhao G
Sci Rep; 2023 Jan; 13(1):882. PubMed ID: 36650267
[TBL] [Abstract][Full Text] [Related]
6. Cancer sensitizing effect of deazaflavin analogs is associated with increased intracellular drug accumulation.
Belhadj Z; Offei S; Jacobson BA; Cambron D; Kratzke RA; Wang Z; Xie J
Eur J Pharm Sci; 2024 Feb; 193():106686. PubMed ID: 38159687
[TBL] [Abstract][Full Text] [Related]
7. Molecular docking studies on thirteen fluoroquinolines with human topoisomerase II a and b.
Jadhav AK; Karuppayil SM
In Silico Pharmacol; 2016 Dec; 5(1):4. PubMed ID: 28667488
[TBL] [Abstract][Full Text] [Related]
8. Topoisomerase I inhibitors and drug resistance.
Parchment RE; Pessina A
Cytotechnology; 1998 Sep; 27(1-3):149-64. PubMed ID: 19002789
[TBL] [Abstract][Full Text] [Related]
9. Copper Complexes as Anticancer Agents Targeting Topoisomerases I and II.
Molinaro C; Martoriati A; Pelinski L; Cailliau K
Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33027952
[TBL] [Abstract][Full Text] [Related]
10. Author Correction: ATM inhibitor KU60019 synergistically sensitizes lung cancer cells to topoisomerase II poisons by multiple mechanisms.
Shu J; Wang X; Yang X; Zhao G
Sci Rep; 2024 Apr; 14(1):8785. PubMed ID: 38627539
[No Abstract] [Full Text] [Related]
11. There's more to enzyme antagonism than inhibition.
Callahan BP; Xu Z
Bioorg Med Chem; 2023 Mar; 82():117231. PubMed ID: 36893527
[TBL] [Abstract][Full Text] [Related]
12. Anticancer Activity of Indeno[1,2-b]-Pyridinol Derivative as a New DNA Minor Groove Binding Catalytic Inhibitor of Topoisomerase IIα.
Jeon KH; Shrestha A; Jang HJ; Kim JA; Sheen N; Seo M; Lee ES; Kwon Y
Biomol Ther (Seoul); 2021 Sep; 29(5):562-570. PubMed ID: 34011695
[TBL] [Abstract][Full Text] [Related]
13. Bacterial terpenome.
Rudolf JD; Alsup TA; Xu B; Li Z
Nat Prod Rep; 2021 May; 38(5):905-980. PubMed ID: 33169126
[TBL] [Abstract][Full Text] [Related]
14. Effects of MnDPDP and ICRF-187 on Doxorubicin-Induced Cardiotoxicity and Anticancer Activity.
Kurz T; Grant D; Andersson RG; Towart R; De Cesare M; Karlsson JO
Transl Oncol; 2012 Aug; 5(4):252-9. PubMed ID: 22937177
[TBL] [Abstract][Full Text] [Related]
15. Cancer survivors in the United States: a review of the literature and a call to action.
Valdivieso M; Kujawa AM; Jones T; Baker LH
Int J Med Sci; 2012; 9(2):163-73. PubMed ID: 22275855
[TBL] [Abstract][Full Text] [Related]
16. Dexrazoxane ameliorates doxorubicin-induced injury in mouse ovarian cells.
Roti Roti EC; Salih SM
Biol Reprod; 2012 Mar; 86(3):96. PubMed ID: 22190700
[TBL] [Abstract][Full Text] [Related]
17. Topoisomerase IIalpha maintains genomic stability through decatenation G(2) checkpoint signaling.
Bower JJ; Karaca GF; Zhou Y; Simpson DA; Cordeiro-Stone M; Kaufmann WK
Oncogene; 2010 Aug; 29(34):4787-99. PubMed ID: 20562910
[TBL] [Abstract][Full Text] [Related]
18. [Prevention, early diagnosis and treatment of chemoextravasation. Practical management in the uro-oncological practice].
Rinnab L; Ringhoffer M; Mayer-Steinacker R; Hautmann RE; Simon J
Urologe A; 2009 Nov; 48(11):1283-4, 1286-90, 1292-4. PubMed ID: 19888614
[TBL] [Abstract][Full Text] [Related]
19. Effect of structural modification at the 4, 3', and 2' positions of doxorubicin on topoisomerase II poisoning, apoptosis, and cytotoxicity in human melanoma cells.
Gruber BM; Anuszewska EL; Bubko I; Goździk A; Fokt I; Priebe W
Arch Immunol Ther Exp (Warsz); 2007; 55(3):193-8. PubMed ID: 17557149
[TBL] [Abstract][Full Text] [Related]
20. Characterisation of cytotoxicity and DNA damage induced by the topoisomerase II-directed bisdioxopiperazine anti-cancer agent ICRF-187 (dexrazoxane) in yeast and mammalian cells.
Jensen LH; Dejligbjerg M; Hansen LT; Grauslund M; Jensen PB; Sehested M
BMC Pharmacol; 2004 Dec; 4():31. PubMed ID: 15575955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
